The video’s core case is that four small-cap names and PLTR each have clear rerating paths if current growth, backlog, or first-commercial revenue keeps compounding: PLTR on exploding commercial adoption, TEM on its first profitable quarter, FLNC on backlog-to-revenue conversion, LWLG on AI-photonic design wins, and AIRJ on first deployments. The common setup is the same: fundamentals already visible in the numbers, but the market still underpricing the duration and scale of the next 12-18 months. The final sponsored read pitches VNRX as a low-cost epigenetics platform with sepsis, cancer, and pet-cancer tests plus near-term catalysts.
The top five picks are framed as having 100%+ upside over the next 12-18 months, with explicit doubling math laid out for each.
PLTR just printed its strongest quarter ever: revenue was $1.935 billion, up 93% y/y and 19% q/q, the highest growth rate ever recorded.
PLTR US commercial revenue rose 149% to $764 million; US commercial bookings jumped 153% to $2.132 billion; 220 deals were closed above $1 million, including 70 above $10 million.
PLTR full-year guidance was raised to roughly $8.15 billion, about 82% growth, and the double case assumes revenue roughly doubles again while the stock holds its current multiple on a much larger business.
TEM posted its first quarterly profit in company history: Q2 revenue was $382.5 million, up 22%; diagnostics was $289.3 million, up 20%; data and apps was $93.2 million, up 28%.
TEM gap net income was $5.6 million versus a $42.8 million loss a year earlier; EPS improved from a 25-cent loss to 3 cents positive; adjusted EBITDA was $8 million, a $13.6 million y/y improvement.
TEM raised full-year revenue guidance to $1.595 billion-$1.605 billion, about 25% growth, and expected full-year adjusted EBITDA of about $65 million, roughly $72 million better than 2025.
TEM was described as trading around $42-plus versus a 52-week high of $104.32, with an ~$8 billion market cap against 2026 guidance of $1.595 billion-$1.605 billion, or about 5x sales.
FLNC faces earnings tomorrow, with expected post-earnings swings of about 5% to 12%, and the business is framed as grid-scale battery storage plus software and operating services that create recurring revenue.
FLNC year-to-date order intake roughly doubled to about $2 billion from $1 billion a year earlier; backlog hit a record 5.6 billion; management reaffirmed 2026 revenue guidance of $3.2 billion-$3.6 billion, $40 million-$60 million in adjusted EBITDA, and about $180 million in ARR.
FLNC Q2 revenue was $464.9 million, up 7.7%; adjusted EBITDA improved to $9.4 million from -$30.4 million a year earlier; losses were cut by about two-thirds.
FLNC has been trading below 1x forward EV/revenue; the thesis depends on the market accepting that the backlog is real and re-rating it toward roughly 2x sales if it proves conversion into profit.
LWLG says four Fortune 500 companies are designing next-generation hardware around its electro-optic polymer, with agreements in place at four major foundries including Silera and Global Foundaries, plus two unnamed, and three more foundries under consideration.
Tower Semiconductor’s agreement targets modulators above 110 GHz for 200-gig and 400-gig architectures; Tower also disclosed $1.3 billion in contracted silicon photonics revenue for 2027 from top customers, with AI infrastructure as the driver.
LWLG’s near-term setup is binary and small-cap sensitive: management targets high-volume production beginning in 2027, is in active negotiations on a material supply and licensing agreement, and any new-name customer or supply deal could force a double or triple over the coming weeks.
AIRJ is a roughly $300 million-$400 million market-cap water-from-air company with a key use in AI data centers; its material absorbs water molecules without chilling and releases them with low-grade or waste heat.
AIRJ’s products are AirJule Prime at about 2,000 liters per day and AirJule Core at about 250 liters per day; a dehumidification variant showed up to 40% energy savings in early tests.
On July 21, AirJuel announced an exclusive commercial partnership with Kubota, which has sole sales rights for multi-unit residential developments across Texas and California, with first deployments planned for Q3 this year.
On July 28, AirJule deployed an AirJule Core system at GV Vernova’s newly opened Frontier Campus in New York; GV Vernova is funding half the deployment in a 50/50 JV structure.
AIRJ also has a licensed relationship with Carrier Global and an exclusive Middle East distributor arrangement with 10X, while a hyperscale data center operator is running economics tests on Prime at specific sites using waste heat and chiller integration.
AIRJ was said to be worth roughly $3,400 million depending on timing, and a double from here was framed as only a $600 million-$700 million company, making first revenue and first deployments the rerating trigger.
VNRX is presented as a multinational epigenetics company built around nucleosomes and low-cost blood tests across sepsis, human cancer, veterinary cancer, and research tools.
VNRX’s pillars are NU.Q NETS for sepsis and immune-related disease, NU.Q Cancer and Capture/SEQ for human cancer detection, NU.Q Vet for dogs and cats, and NU.Q Discover for assay kits sold to pharma and academic labs.
VNRX says sepsis cases are about 166 million a year, all-cause sepsis-related deaths in 2021 were about 31.5% of total global deaths, and NU.Q NETS carries an annualized addressable market of about $3.8 billion.
For cancer, Coalition’s blinded validation cohort reportedly detected over 95% of stage 1 and stage 2 cancers at 95% specificity, while VNRX sizes multi-cancer early detection at about $23 billion annually and another $13 billion if used in minimal residual disease monitoring.
VNRX’s K9 cancer test is already commercially available in more than 20 countries; in May the company submitted the feline manuscript at 97% specificity, and the prototype assay detected 86% of feline lymphomas.
VNRX says the companion-animal pillar is worth over $1 billion annually and that a working feline test could roughly double that addressable market.
VNRX’s strategy is to outlicense the technology to large diagnostics and liquid-biopsy companies, taking upfronts, milestones, and royalties while keeping incremental costs low; a French DETECTS program, the feline-llymphoma publication, and a $5 million milestone are the near-term catalysts.